Tags

Type your tag names separated by a space and hit enter

Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial.
Int J Androl. 2012 Apr; 35(2):190-5.IJ

Abstract

Extracorporeal shock wave therapy improves erectile function in patients with Peyronie's disease. However, erectile dysfunction still persists in many cases. We aimed to investigate the effects of extracorporeal shock wave therapy plus tadalafil 5 mg once daily in the management of patients with Peyronie's disease and erectile dysfunction not previously treated. One hundred patients were enrolled in a prospective, randomized, controlled study. Patients were randomly allocated to receive either extracorporeal shock wave therapy alone for 4 weeks (n = 50) or extracorporeal shock wave therapy plus tadalafil 5 mg once daily for 4 weeks (n = 50). Main outcome measures were: erectile function (evaluated through the shortened version of the International Index of Erectile Function), pain during erection (evaluated through a Visual Analog Scale), plaque size, penile curvature and quality of life (evaluated through an internal questionnaire). Follow-up evaluations were performed after 12 and 24 weeks. In both groups, at 12 weeks follow-up, mean Visual Analog Scale score, mean International Index of Erectile Function score and mean quality of life score ameliorated significantly while mean plaque size and mean curvature degree were unchanged. Intergroup analysis revealed a significantly higher mean International Index of Erectile Function score and quality of life score in patients receiving the combination. After 24 weeks, intergroup analysis revealed a significantly higher mean International Index of Erectile Function score and mean quality of life score in patients that received extracorporeal shock wave therapy plus tadalafil. In conclusion extracorporeal shock wave therapy plus tadalafil 5 mg once daily may represent a valid conservative strategy for the management of patients with Peyronie's disease and erectile dysfunction.

Authors+Show Affiliations

Department of Urology, University Federico II of Naples, Naples, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

22085227

Citation

Palmieri, A, et al. "Tadalafil once Daily and Extracorporeal Shock Wave Therapy in the Management of Patients With Peyronie's Disease and Erectile Dysfunction: Results From a Prospective Randomized Trial." International Journal of Andrology, vol. 35, no. 2, 2012, pp. 190-5.
Palmieri A, Imbimbo C, Creta M, et al. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012;35(2):190-5.
Palmieri, A., Imbimbo, C., Creta, M., Verze, P., Fusco, F., & Mirone, V. (2012). Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. International Journal of Andrology, 35(2), 190-5. https://doi.org/10.1111/j.1365-2605.2011.01226.x
Palmieri A, et al. Tadalafil once Daily and Extracorporeal Shock Wave Therapy in the Management of Patients With Peyronie's Disease and Erectile Dysfunction: Results From a Prospective Randomized Trial. Int J Androl. 2012;35(2):190-5. PubMed PMID: 22085227.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. AU - Palmieri,A, AU - Imbimbo,C, AU - Creta,M, AU - Verze,P, AU - Fusco,F, AU - Mirone,V, Y1 - 2011/11/15/ PY - 2011/11/17/entrez PY - 2011/11/17/pubmed PY - 2012/7/11/medline SP - 190 EP - 5 JF - International journal of andrology JO - Int J Androl VL - 35 IS - 2 N2 - Extracorporeal shock wave therapy improves erectile function in patients with Peyronie's disease. However, erectile dysfunction still persists in many cases. We aimed to investigate the effects of extracorporeal shock wave therapy plus tadalafil 5 mg once daily in the management of patients with Peyronie's disease and erectile dysfunction not previously treated. One hundred patients were enrolled in a prospective, randomized, controlled study. Patients were randomly allocated to receive either extracorporeal shock wave therapy alone for 4 weeks (n = 50) or extracorporeal shock wave therapy plus tadalafil 5 mg once daily for 4 weeks (n = 50). Main outcome measures were: erectile function (evaluated through the shortened version of the International Index of Erectile Function), pain during erection (evaluated through a Visual Analog Scale), plaque size, penile curvature and quality of life (evaluated through an internal questionnaire). Follow-up evaluations were performed after 12 and 24 weeks. In both groups, at 12 weeks follow-up, mean Visual Analog Scale score, mean International Index of Erectile Function score and mean quality of life score ameliorated significantly while mean plaque size and mean curvature degree were unchanged. Intergroup analysis revealed a significantly higher mean International Index of Erectile Function score and quality of life score in patients receiving the combination. After 24 weeks, intergroup analysis revealed a significantly higher mean International Index of Erectile Function score and mean quality of life score in patients that received extracorporeal shock wave therapy plus tadalafil. In conclusion extracorporeal shock wave therapy plus tadalafil 5 mg once daily may represent a valid conservative strategy for the management of patients with Peyronie's disease and erectile dysfunction. SN - 1365-2605 UR - https://wwww.unboundmedicine.com/medline/citation/22085227/Tadalafil_once_daily_and_extracorporeal_shock_wave_therapy_in_the_management_of_patients_with_Peyronie's_disease_and_erectile_dysfunction:_results_from_a_prospective_randomized_trial_ L2 - https://doi.org/10.1111/j.1365-2605.2011.01226.x DB - PRIME DP - Unbound Medicine ER -